Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | BTK | Q06187 | 1/20 | 0.69 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.55 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001794 | 0.90 | EGFR (0.84) | EGFRBTKMAP4K1ULK1INSR | |
| SCHEMBL25001849 | 0.90 | EGFR (0.57) | EGFRBTKMAP4K1 | |
| SCHEMBL25001574 | 0.89 | EGFR (0.60) | EGFRBTKMAP4K1 | |
| SCHEMBL25001623 | 0.89 | EGFR (0.64) | EGFRBTKMAP4K1 | |
| SCHEMBL25001983 | 0.88 | EGFR (0.57) | EGFRBTKMAP4K1ULK1INSR | |
| SCHEMBL25001385 | 0.86 | EGFR (0.60) | EGFRBTKMAP4K1ULK1INSR | |
| SCHEMBL30176224 | 0.85 | EGFR (0.57) | EGFRBTKMAP4K1ULK1INSR | |
| SCHEMBL25002442 | 0.85 | EGFR (0.54) | EGFRBTKMAP4K1ULK1INSR | |
| SCHEMBL25001525 | 0.85 | EGFR (0.62) | EGFRBTK | |
| SCHEMBL23420454 | 0.84 | EGFR (0.67) | EGFRBTKMAP4K1ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885BTK 265/4885MAP4K1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.